Companies › Enanta Pharmaceuticals
2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Immunology, Infectious disease, Respiratory; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Zelicapavir RSV non-fusion replication inhibitor | RSV | Phase 2 | RSV Infection; RSV | Dec 2026 |
| EDP-978 | – | Phase 1 | Chronic Inducible Urticaria | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07540910 | EDP-978 | Phase 1 | Chronic Inducible Urticaria | Immunology | Nov 2026 |
| NCT07482657 | Zelicapavir | Phase 2 | RSV Infection | Infectious disease | Dec 2026 |
| NCT07908381 | Zelicapavir | Phase 2 | RSV | Respiratory | Jul 2029 |
Cash and short-term investments of $190m on 2026-06-30; operating cash outflow about $39m a year; runway about 59 months at that burn, to May 2031; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Sanofi ModernaTX AstraZeneca MAXVAX Biotechnology Limited Liability Company Shenzhen Shenxin Biotechnology GSK
Avalyn Pharma Sagimet Biosciences Thirty Respiratory Kymera Therapeutics Shanghai Longwood Biopharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.